Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ — Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.